Nov. 21 Preclinical Quick Takes: Excision applies CRISPR editing to herpes, John Cunningham viruses; plus Caribou, Oligomerix, Kymab and Gladstone-Boston Univer

Excision targets CRISPR to herpes, JC viruses
Excision BioTherapeutics Inc. and collaborators at Temple University presented a pair of posters at the International Symposium on NeuroVirology meeting in Atlanta showing CRISPR-Cas9 gene editing could treat herpes simplex virus (HSV) and John Cunningham (JC) virus infections. Adeno-associated viral (AAV)